Inotek Pharmaceuticals Initiates Phase 2 Dose-ranging Trial of a Fixed-Dose Combination of Trabodenoson, a Novel Treatment for Glaucoma, and Latanoprost (Inotek Pharmaceuticals Corporation)

(Source: Inotek Pharmaceuticals Corporation) -Data Expected in 2017- LEXINGTON, Mass--(BUSINESS WIRE)--Jul. 12, 2016-- Inotek Pharmaceuticals Corporation (NASDAQ: ITEK), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for glaucoma and other eye diseases, today announced the initiation of a Phase 2 dose-ranging trial of a fixed-dose combination (FDC) of trabodenoson and latanoprost. Glaucoma is one of the leading causes of blindness, and occurs when there is damage to the optic nerve as a result of elevated eye pressure. While the goal of glaucoma treatment is to preserve vision; lowering intraocular pressure (IOP) -a...